102 related articles for article (PubMed ID: 15179191)
21. Significance of serum protein S100 levels in screening for melanoma metastasis: does protein S100 enable early detection of melanoma recurrence?
Schlagenhauff B; Schittek B; Ellwanger U; Stroebel W; Blum A; Schwarz M; Rassner G; Garbe C
Melanoma Res; 2000 Oct; 10(5):451-9. PubMed ID: 11095406
[TBL] [Abstract][Full Text] [Related]
22. S100beta as a predictor of brain metastases: brain versus cerebrovascular damage.
Vogelbaum MA; Masaryk T; Mazzone P; Mekhail T; Fazio V; McCartney S; Marchi N; Kanner A; Janigro D
Cancer; 2005 Aug; 104(4):817-24. PubMed ID: 15971200
[TBL] [Abstract][Full Text] [Related]
23. Tumor type M2 pyruvate kinase (TuM2-PK) as a novel plasma tumor marker in melanoma.
Ugurel S; Bell N; Sucker A; Zimpfer A; Rittgen W; Schadendorf D
Int J Cancer; 2005 Dec; 117(5):825-30. PubMed ID: 15957165
[TBL] [Abstract][Full Text] [Related]
24. Melanoma-inhibitory activity protein concentrations in blood of melanoma patients treated with immunotherapy.
Dréau D; Bosserhoff AK; White RL; Buettner R; Holder WD
Oncol Res; 1999; 11(1):55-61. PubMed ID: 10451031
[TBL] [Abstract][Full Text] [Related]
25. Serum S100--a marker for disease monitoring in metastatic melanoma.
Henze G; Dummer R; Joller-Jemelka HI; Böni R; Burg G
Dermatology; 1997; 194(3):208-12. PubMed ID: 9187834
[TBL] [Abstract][Full Text] [Related]
26. Risk and outcome in metastatic malignant melanoma patients receiving DTIC, cisplatin, BCNU and tamoxifen followed by immunotherapy with interleukin 2 and interferon alpha2a.
Hoffmann R; Müller I; Neuber K; Lassmann S; Buer J; Probst M; Oevermann K; Franzke A; Kirchner H; Ganser A; Atzpodien J
Br J Cancer; 1998 Oct; 78(8):1076-80. PubMed ID: 9792153
[TBL] [Abstract][Full Text] [Related]
27. Early postoperative serum S100 beta levels predict ongoing brain damage after meningioma surgery: a prospective observational study.
Einav S; Shoshan Y; Ovadia H; Matot I; Hersch M; Itshayek E
Crit Care; 2006; 10(5):R141. PubMed ID: 17020600
[TBL] [Abstract][Full Text] [Related]
28. Activity of continuous infusion plus pulse interleukin-2 with famotidine in patients with metastatic kidney cancer or melanoma previously treated with interleukin-2.
Quan WD; Walker PR; Quan FM; Ramirez M; Elsamaloty HM; Ghai V; Vinogradov M; Liles DK
Cancer Biother Radiopharm; 2006 Oct; 21(5):437-42. PubMed ID: 17105418
[TBL] [Abstract][Full Text] [Related]
29. Angiopoietin-2 levels are associated with disease progression in metastatic malignant melanoma.
Helfrich I; Edler L; Sucker A; Thomas M; Christian S; Schadendorf D; Augustin HG
Clin Cancer Res; 2009 Feb; 15(4):1384-92. PubMed ID: 19228739
[TBL] [Abstract][Full Text] [Related]
30. Interleukin-2-based immunotherapy and chemoimmunotherapy in metastatic melanoma.
Keilholz U; Scheibenbogen C; Brossart P; Möhler T; Tilgen W; Hunstein W
Recent Results Cancer Res; 1995; 139():383-90. PubMed ID: 7597305
[TBL] [Abstract][Full Text] [Related]
31. Melanoma-inhibiting activity, a novel serum marker for progression of malignant melanoma.
Bosserhoff AK; Kaufmann M; Kaluza B; Bartke I; Zirngibl H; Hein R; Stolz W; Buettner R
Cancer Res; 1997 Aug; 57(15):3149-53. PubMed ID: 9242442
[TBL] [Abstract][Full Text] [Related]
32. Rising levels of serum S100 protein precede other evidence of disease progression in patients with malignant melanoma.
Jury CS; McAllister EJ; MacKie RM
Br J Dermatol; 2000 Aug; 143(2):269-74. PubMed ID: 10951132
[TBL] [Abstract][Full Text] [Related]
33. Acute decompression illness and serum s100beta levels: a prospective observational pilot study.
Poff DJ; Wong R; Bulsara M
Undersea Hyperb Med; 2007; 34(5):359-67. PubMed ID: 18019087
[TBL] [Abstract][Full Text] [Related]
34. Normal values of serum S-100B predict prolonged survival for stage IV melanoma patients.
Smit LH; Korse CM; Hart AA; Bonfrer JM; Haanen JB; Kerst JM; Nieweg OE; de Gast GC
Eur J Cancer; 2005 Feb; 41(3):386-92. PubMed ID: 15691637
[TBL] [Abstract][Full Text] [Related]
35. [Serum S100 protein and NSE levels and significance of changes after treatment in patients with severe OSAHS].
Feng X; Kang X; Zhou F; Xiao X; Wang J
Lin Chuang Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2014 Nov; 28(21):1665-9. PubMed ID: 25735097
[TBL] [Abstract][Full Text] [Related]
36. Accuracy of the S100β protein as a marker of brain damage in traumatic brain injury.
Egea-Guerrero JJ; Revuelto-Rey J; Murillo-Cabezas F; Muñoz-Sánchez MA; Vilches-Arenas A; Sánchez-Linares P; Domínguez-Roldán JM; León-Carrión J
Brain Inj; 2012; 26(1):76-82. PubMed ID: 22149446
[TBL] [Abstract][Full Text] [Related]
37. [A new approach in the treatment of metastatic melanoma: adoptive immunotherapy using lymphokine-activated killer cells and interleukin 2].
Keilholz U; Welters H; Dummer R; Tilgen W; Hunstein W
Hautarzt; 1988 Jun; 39(6):378-81. PubMed ID: 3261288
[TBL] [Abstract][Full Text] [Related]
38. Increased GFAP and S100beta but not NSE serum levels after subarachnoid haemorrhage are associated with clinical severity.
Vos PE; van Gils M; Beems T; Zimmerman C; Verbeek MM
Eur J Neurol; 2006 Jun; 13(6):632-8. PubMed ID: 16796588
[TBL] [Abstract][Full Text] [Related]
39. Updated analysis of an outpatient chemoimmunotherapy regimen for treating metastatic melanoma.
Thompson JA; Gold PJ; Markowitz DR; Byrd DR; Lindgren CG; Fefer A
Cancer J Sci Am; 1997 Dec; 3 Suppl 1():S29-34. PubMed ID: 9457390
[TBL] [Abstract][Full Text] [Related]
40. Serum S100beta: a noninvasive marker of blood-brain barrier function and brain lesions.
Kanner AA; Marchi N; Fazio V; Mayberg MR; Koltz MT; Siomin V; Stevens GH; Masaryk T; Aumayr B; Vogelbaum MA; Barnett GH; Janigro D
Cancer; 2003 Jun; 97(11):2806-13. PubMed ID: 12767094
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
